Literature DB >> 30215202

Circulating Leptin and Branched Chain Amino Acids-Correlation with Intraductal Papillary Mucinous Neoplasm Dysplastic Grade.

Michele T Yip-Schneider1,2,3,4, Rachel Simpson1,4, Rosalie A Carr1,4, Huangbing Wu1,4, Hao Fan5, Ziyue Liu6,7, Murray Korc3,8,9, Jianjun Zhang10,11, C Max Schmidt12,13,14,15,16.   

Abstract

BACKGROUND: The most common type of mucinous pancreatic cyst that may progress to pancreatic cancer is intraductal papillary mucinous neoplasm (IPMN). Low-risk IPMN with low-/moderate-grade dysplasia may be safely watched, whereas high-risk IPMN with high-grade dysplasia or invasive components should undergo resection. However, there is currently no reliable means of making this distinction. We hypothesize that blood concentrations of insulin resistance biomarkers may aid in the differentiation of low- and high-risk IPMN.
METHODS: Plasma/serum was collected from consented patients undergoing pancreatic resection. IPMN diagnosis and dysplastic grade were confirmed by surgical pathology. The study included 235 IPMN (166 low/moderate grade, 39 high grade, 30 invasive). Circulating levels of leptin, branched chain amino acids (BCAA), and retinol-binding protein-4 (RBP-4) were measured by enzyme-linked immunoassay and correlated with surgical pathology.
RESULTS: Circulating leptin levels (mean ± SE) were significantly higher in patients with low/moderate IPMN than in high-grade/invasive IPMN (15,803 ± 1686 vs. 10,275 ± 1228 pg/ml; p = 0.0086). Leptin levels were positively correlated with BMI (r = 0.65, p < 0.0001) and were higher in females (p < 0.0001). Stratified analysis showed that mean leptin levels were significantly different between low/moderate and high/invasive IPMNs only in females (24,383 ± 2748 vs. 16,295 ± 2040 pg/ml; p = 0.020). Conversely, circulating BCAA levels were lower in low/moderate IPMN than in high-grade/invasive IPMN (0.38 ± 0.007 vs. 0.42 ± 0.01 mM; p = 0.011). No significant differences in RBP-4 levels were observed.
CONCLUSIONS: Circulating leptin in females and BCAA correlates with IPMN dysplastic grade and, if combined with clinical characteristics, have the potential to improve clinical decision-making.

Entities:  

Keywords:  BCAA; Biomarker; IPMN; Leptin; Pancreatic cyst

Mesh:

Substances:

Year:  2018        PMID: 30215202      PMCID: PMC6416083          DOI: 10.1007/s11605-018-3963-y

Source DB:  PubMed          Journal:  J Gastrointest Surg        ISSN: 1091-255X            Impact factor:   3.452


  29 in total

1.  Physical activity, obesity, height, and the risk of pancreatic cancer.

Authors:  D S Michaud; E Giovannucci; W C Willett; G A Colditz; M J Stampfer; C S Fuchs
Journal:  JAMA       Date:  2001 Aug 22-29       Impact factor: 56.272

2.  Insulin, glucose, insulin resistance, and pancreatic cancer in male smokers.

Authors:  Rachael Z Stolzenberg-Solomon; Barry I Graubard; Suresh Chari; Paul Limburg; Philip R Taylor; Jarmo Virtamo; Demetrius Albanes
Journal:  JAMA       Date:  2005-12-14       Impact factor: 56.272

3.  Fasting serum glucose level and cancer risk in Korean men and women.

Authors:  Sun Ha Jee; Heechoul Ohrr; Jae Woong Sull; Ji Eun Yun; Min Ji; Jonathan M Samet
Journal:  JAMA       Date:  2005-01-12       Impact factor: 56.272

4.  Serum retinol binding protein 4 contributes to insulin resistance in obesity and type 2 diabetes.

Authors:  Qin Yang; Timothy E Graham; Nimesh Mody; Frederic Preitner; Odile D Peroni; Janice M Zabolotny; Ko Kotani; Loredana Quadro; Barbara B Kahn
Journal:  Nature       Date:  2005-07-21       Impact factor: 49.962

5.  PGE(2) in pancreatic cyst fluid helps differentiate IPMN from MCN and predict IPMN dysplasia.

Authors:  C Max Schmidt; Michele T Yip-Schneider; Matthew C Ralstin; Sabrina Wentz; John DeWitt; Stuart Sherman; Thomas J Howard; Lee McHenry; Sarah Dutkevitch; Michael Goggins; Attila Nakeeb; Keith D Lillemoe
Journal:  J Gastrointest Surg       Date:  2007-11-20       Impact factor: 3.452

6.  Evaluation of the guidelines for management of pancreatic branch-duct intraductal papillary mucinous neoplasm.

Authors:  Raymond S Tang; Benjamin Weinberg; David W Dawson; Howard Reber; Oscar J Hines; James S Tomlinson; Vinika Chaudhari; Steven Raman; James J Farrell
Journal:  Clin Gastroenterol Hepatol       Date:  2008-07       Impact factor: 11.382

Review 7.  Pancreatic cysts: preoperative diagnosis and clinical management.

Authors:  Martha Bishop Pitman; Kent Lewandrowski; Jian Shen; Dushyant Sahani; William Brugge; Carlos Fernandez-del Castillo
Journal:  Cancer Cytopathol       Date:  2010-02-25       Impact factor: 5.284

8.  Spectrum of cystic neoplasms of the pancreas and their surgical management.

Authors:  Maureen K Sheehan; Kimberly Beck; Jack Pickleman; Gerard V Aranha
Journal:  Arch Surg       Date:  2003-06

9.  Type-II diabetes and pancreatic cancer: a meta-analysis of 36 studies.

Authors:  R Huxley; A Ansary-Moghaddam; A Berrington de González; F Barzi; M Woodward
Journal:  Br J Cancer       Date:  2005-06-06       Impact factor: 7.640

Review 10.  Update on diabetes mellitus.

Authors:  Murray Korc
Journal:  Dis Markers       Date:  2004       Impact factor: 3.434

View more
  2 in total

1.  Genetic and Circulating Biomarker Data Improve Risk Prediction for Pancreatic Cancer in the General Population.

Authors:  Brian M Wolpin; Peter Kraft; Jihye Kim; Chen Yuan; Ana Babic; Ying Bao; Clary B Clish; Michael N Pollak; Laufey T Amundadottir; Alison P Klein; Rachael Z Stolzenberg-Solomon; Pari V Pandharipande; Lauren K Brais; Marisa W Welch; Kimmie Ng; Edward L Giovannucci; Howard D Sesso; JoAnn E Manson; Meir J Stampfer; Charles S Fuchs
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2020-04-22       Impact factor: 4.254

Review 2.  Recent Metabolomics Analysis in Tumor Metabolism Reprogramming.

Authors:  Jingjing Han; Qian Li; Yu Chen; Yonglin Yang
Journal:  Front Mol Biosci       Date:  2021-11-25
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.